Abiraterone: Finance
Commons · Question 87906 · Tabled 4 Nov 2025 · Department of Health and Social Care · Official record
Answered 17 Nov 2025
Question
Asked by Louie French
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 October 2025 to Question 83371 on Abiraterone: Finance, what steps he is taking to secure recurrent budget allocation for abiraterone for use in cases of high-risk non-
Answer
Answered by Zubir Ahmed, 17 Nov 2025
Abiraterone is not licensed for use in the treatment of high-risk, non-metastatic hormone-sensitive prostate cancer, and as such, cannot be evaluated by the National Institute for Health and Care Excellence (NICE) for routine use on the National Health Se...